With a rich background as a Chief Financial Officer (CFO), Aleksey Krylov is a seasoned professional with in-depth expertise in the dynamic arenas of life sciences and medical technology. Aleksey presents a remarkable portfolio of over 70 successful fundraising and M&A transactions, showcasing his adeptness in steering companies through diverse strategic opportunities.

Holding an MBA from Columbia Business School and a Bachelor of Science in Business Administration from Babson College, Aleksey’s financial acumen is further illuminated in his transformative role as the CFO of CytoImmune Therapeutics where he secured over $100 million in funding.

As the CFO of DIH International, Aleksey Krylov strategically positioned the Swiss-Chinese medical equipment manufacturer for a NASDAQ public offering, emphasizing growth optimization and maximizing shareholder value. At SELLAS Life Sciences, he led a successful reverse merger, propelling the company to a market capitalization of several hundred million dollars. He also took care of investments of over $500 million across diverse industries as a family office investment professional.

Aleksey Krylov considers himself fortunate for his career success and entrepreneurial ventures. Driven by a desire to give back, he seeks to share ideas and thoughts that could benefit fellow entrepreneurs on their journeys. Aleksey Krylov’s impressive track record as a CFO not only witnesses his financial prowess but also proves his strong commitment to fostering growth and innovation in the business world.